ArticleInternational journal of general medicine2025
Effect of Adjuvant Conbercept on Patients with Macular Edema Induced by Diabetic Retinopathy and Retinal Vein Occlusion Undergoing Laser Treatment: Impact on Symptom Improvement.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effect of adjuvant Conbercept in patients with macular edema caused by diabetic retinopathy (DR) or retinal vein occlusion (RVO) undergoing laser therapy, and its impact on symptom improvement. Methods: This retrospective cohort study analyzed 63 patients treated between January 2022 and January 2025. Patients were assigned to a control group (n=31, laser alone) or an observation group (n=32, laser plus Conbercept). Outcomes included clinical efficacy, symptom improvement time (fundus hemorrhage absorption, exudate absorption, macular edema resolution), best corrected visual acuity (BCVA), retinal thickness (central fovea, superior, nasal, inferior, temporal), and adverse events. Results: The total effective rate was higher in the observation group (96.88%) than in the control group (74.19%) (P<0.05). Symptom improvement times were shorter in the observation group: fundus hemorrhage absorption (2.32±0.25 vs 3.23±0.37 weeks), exudate absorption (10.23±1.38 vs 12.19±1.46 weeks), and macular edema resolution (4.31±0.32 vs 5.69±0.43 weeks) (all P<0.05). BCVA improved significantly in both groups at 1 and 3 months, with greater improvement in the observation group (P<0.05). Retinal thickness decreased in all measured regions in both groups, with more pronounced reductions in the observation group (P<0.05). Adverse event rates did not differ significantly (9.38% vs 12.90%, P>0.05). Conclusion: Conbercept adjunctive to laser therapy in DR- or RVO-related macular edema enhances clinical efficacy, accelerates symptom resolution, improves visual and retinal function, and does not increase adverse reaction risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.